About this trial
This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also used to treat pleural effusions. The goal of this clinical research study is to learn if adding doxycycline to the use of an IPC can lead to shorter treatment times with IPCs.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Outpatients with MPE undergoing IPC placement
Sufficient mental capacity to provide informed consent and answer Short-Form Six-Dimension health index (SF-6D) and Borg score questions
Inpatients that are expected to be discharged within 5 days of receiving an indwelling pleural catheter
Disqualifiers
Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)
Inability or unwillingness to give informed consent
Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
Pregnancy
Trial population
Outpatients with MPE undergoing IPC placement
Trial design
Case-only
Prospective
Treatments tested in this trial
Doxycycline
DrugReceive via IPC
Indwelling Catheter
DeviceReceive IPC
Quality-of-Life Assessment
Procedure/SurgeryAncillary studies
Questionnaire Administration
Other interventionAncillary studies
Survey Administration
Other interventionAncillary studies
Treatment groups
Trial outcomes
Primary outcomes
Time to pleural catheter removal
This outcome will be analyzed by cause-specific hazard Cox model with treatment group as a covariate. Whenever a catheter is removed, the cause for removal will be documented. For the analysis, causes will include removal due to decreased drainage (i.e., as per plan) as well as removal due to complications (e.g. infection, empyema, refractory pain) or other reasons (e.g. catheter plugged but no complication to the patient, patient preference without a complication). We will also analyze time to catheter removal for any cause and conduct pre-specified secondary analyses to evaluate the effect of fluid drainage amount (i.e., how much was being put out from the indwelling pleural catheter (IPC) the day of IPC placement and on the day of doxycycline instillation) and size of residual effusion as assessed by chest x-ray (CXR) (on day of IPC placement and day of doxycycline instillation) on time to catheter removal.
Secondary outcomes
Recurrence of effusion requiring drainage after IPC
Indwelling pleural catheters (IPC) complications
Quality-adjusted survival measured using Short-Form Six-Dimension health index (SF-6D)
Will use the Kaplan-Meier product-limit method to estimate median quality-adjusted life years (QALYs) following IPC placement.
Change in dyspnea using Borg score
Will use paired t-test to compare baseline and 1 month Borg scores and utilities. A generalized linear model will be used to evaluate whether other variables have any impact on the pairwise differences between baseline and 1 month.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator